Non-stimulant ADHD medications are a class of drugs that treat attention, impulsivity, and hyperactivity symptoms without the stimulant mechanism that characterizes methylphenidate and amphetamines. They are often prescribed when stimulants cause intolerable side effects, when there is a risk of substance misuse, or when a person simply responds better to a different approach. Four non-stimulant medications currently hold FDA approval for ADHD.
What non-stimulant ADHD medications are available?
Four FDA-approved non-stimulant medications are currently used for ADHD. They fall into two classes: norepinephrine reuptake inhibitors (atomoxetine and viloxazine extended-release) and alpha-2 adrenergic agonists (guanfacine extended-release and clonidine extended-release). Each works through a distinct mechanism, and a prescriber selects among them based on individual symptoms, health history, and treatment goals.
Atomoxetine (Strattera)
Atomoxetine was the first non-stimulant approved specifically for ADHD and remains the most extensively studied option in adults. It selectively inhibits the reuptake of norepinephrine, increasing the availability of this neurotransmitter in the prefrontal cortex. Clinical guidelines in several countries, including NICE in the UK and CADDRA in Canada, list atomoxetine as a second-line pharmacological option when stimulants are not suitable (Brancati et al., 2024) [3].
Viloxazine extended-release (Qelbree)
Viloxazine ER is a selective norepinephrine reuptake inhibitor that also modulates serotonin activity. It was approved by the FDA in 2021 for pediatric ADHD (ages 6 to 17) and has a longer history as an antidepressant in Europe (Haddad et al., 2022) [4]. Research into its use in adults is ongoing, and some clinicians prescribe it off-label for adult ADHD when other options have not worked well. Phase 2 and 3 trials demonstrated significant symptom improvement compared to placebo in pediatric populations.
Guanfacine extended-release (Intuniv)
Guanfacine ER is an alpha-2A adrenergic agonist originally developed to treat high blood pressure. It works by stimulating receptors in the prefrontal cortex that strengthen working memory and attention regulation. In the US, it holds FDA approval for ADHD in children and adolescents, and clinicians may prescribe it off-label for adults. NICE guidelines in the UK include guanfacine as a treatment option when stimulants and atomoxetine are not appropriate.
Clonidine extended-release (Kapvay)
Clonidine ER is another alpha-2 adrenergic agonist, though it is less selective than guanfacine. It has FDA approval for pediatric ADHD and is sometimes used off-label in adults. Clonidine can be particularly helpful for hyperactivity, impulsivity, and sleep difficulties that accompany ADHD, because its calming mechanism can reduce arousal at bedtime (Vilus et al., 2025) [6].
For a broader comparison of all medication classes, see our complete ADHD medications guide.
Quick-reference comparison of approved non-stimulant medications
| Feature | Atomoxetine | Viloxazine ER | Guanfacine ER | Clonidine ER |
|---|---|---|---|---|
| Drug class | Norepinephrine reuptake inhibitor | Norepinephrine reuptake inhibitor (+ serotonin modulation) | Alpha-2A agonist | Alpha-2 agonist |
| FDA-approved for adults? | Yes | Not yet (pediatric approval; adult trials ongoing) | Off-label in adults | Off-label in adults |
| Typical onset to full effect | 4 to 6 weeks | 2 to 4 weeks (pediatric data) | 2 to 4 weeks | 2 to 4 weeks |
| Misuse potential | None | None | None | None |
| Common side effects | Nausea, dry mouth, decreased appetite | Nausea, fatigue, headache | Drowsiness, low blood pressure, fatigue | Drowsiness, dry mouth, low blood pressure |
How do non-stimulants work differently from stimulants?
Non-stimulants primarily increase norepinephrine availability or modulate adrenergic receptors, rather than directly boosting dopamine in the way stimulants do. This difference in mechanism explains why non-stimulants take longer to reach full effect and why they carry no risk of dependence or misuse (NCBI Bookshelf, 2024) [1].
Stimulant medications (methylphenidate and amphetamines) work by rapidly increasing dopamine and norepinephrine levels in the brain. Many people notice effects within the first hour of taking a dose. Non-stimulants, by contrast, build their effect gradually over days to weeks as neurotransmitter systems adjust. This slower onset can feel frustrating at first, but it also means the medication provides steady, around-the-clock coverage without the peaks and troughs some people experience with stimulants.
"Stimulants are drugs with a rapid effect, but they also have the potential for dependence, misuse, and diversion; nonstimulants may take longer to have an effect, but they do not have the same potential for drug misuse." NCBI Bookshelf (CADTH Report), 2024 [1]
The norepinephrine reuptake inhibitors (atomoxetine and viloxazine) block the transporter that removes norepinephrine from the synapse, keeping more of it available to support attention and executive function. The alpha-2 agonists (guanfacine and clonidine) take a different approach: they directly stimulate receptors in the prefrontal cortex that help regulate impulse control, working memory, and emotional responses. For a detailed side-by-side breakdown, see our stimulants vs. non-stimulants comparison.
Who benefits most from non-stimulant medication?
People with co-occurring anxiety or substance use history are often strong candidates for non-stimulant treatment.
Non-stimulants may be a good fit when stimulants cause significant side effects, when a person has a history of substance use, when certain co-occurring conditions are present, or when the individual prefers to avoid controlled substances. They are legitimate treatment options, not a fallback for people who "failed" stimulants (Newcorn et al., 2022) [2].
Several specific situations make non-stimulants worth discussing with a prescriber:
- Intolerable stimulant side effects. Some adults experience insomnia, significant appetite loss, or increased anxiety with stimulants that does not resolve with dose adjustments.
- History of substance use. Because non-stimulants have no misuse potential, they can be a safer choice for adults with a current or past substance use disorder.
- Co-occurring anxiety or tic disorders. Guanfacine and clonidine can help reduce anxiety-related arousal and tics, which stimulants may sometimes worsen in some people.
- Cardiovascular concerns. Alpha-2 agonists lower blood pressure rather than raising it, which may be relevant for adults with certain heart conditions (though all ADHD medications require cardiovascular screening).
- Incomplete stimulant response. Non-stimulants can be added to a stimulant regimen when the stimulant alone does not fully address symptoms. This combination approach, called augmentation, is a recognized clinical strategy (Newcorn et al., 2022) [2].
If you are still exploring whether ADHD might explain your symptoms, you can take a free ADHD screening quiz as a starting point before speaking with a clinician.
Checklist: questions to ask your prescriber about non-stimulants
Use this list to prepare for a medication conversation. Bring it to your appointment or keep it on your phone:
- Have we ruled out medical conditions that could mimic or worsen ADHD symptoms?
- Based on my health history, which non-stimulant class (norepinephrine reuptake inhibitor or alpha-2 agonist) makes the most sense to try first?
- How long should I expect to wait before judging whether this medication is working?
- What side effects should I watch for in the first few weeks, and which ones warrant calling your office?
- Should I track my symptoms during the trial period, and if so, what should I record?
- If this medication does not work well enough, what is the next step: a dose change, a switch, or adding a second medication?
- Are there any interactions with medications or supplements I am already taking?
- How will we handle follow-up appointments during the titration period?
What is the timeline for non-stimulant medications to work?
Non-stimulant medications typically take two to six weeks to reach full effect, unlike stimulants that work within hours.
Most non-stimulant ADHD medications take two to six weeks to reach their full therapeutic effect. Atomoxetine is generally the slowest, with many adults noticing meaningful improvement around weeks four to six. Guanfacine, clonidine, and viloxazine may show initial effects somewhat earlier, often within two to four weeks, though full benefits continue to build.
This timeline is one of the biggest practical differences from stimulants. A person starting a stimulant often knows within the first day or two whether it is helping. With non-stimulants, the gradual onset means you need patience and a clear plan for tracking symptoms over several weeks. Many clinicians recommend keeping a brief daily log of focus, mood, energy, and sleep quality so that both you and your prescriber can identify trends that might not be obvious day to day.
Dose titration also plays a role. Prescribers typically start at a low dose and increase gradually over weeks, both to minimize side effects and to find the right therapeutic level. This means the first week or two may not reflect what the medication can do at its target dose.
What side effects should you expect?
Side effects vary across the four approved non-stimulants, but they are generally milder than the side effects many people associate with stimulants. The norepinephrine reuptake inhibitors (atomoxetine and viloxazine) most commonly cause nausea, decreased appetite, and dry mouth. The alpha-2 agonists (guanfacine and clonidine) are more likely to cause drowsiness, fatigue, and low blood pressure (Brancati et al., 2024) [3].
Some specific considerations for each medication:
- Atomoxetine can cause nausea that is often worst in the first few weeks and may improve with time. Taking it with food can help. Rare but serious side effects include liver injury (very uncommon) and suicidal thinking in young adults, which is why prescribers monitor closely during the early treatment period.
- Viloxazine ER shares the nausea and fatigue profile. Because it modulates serotonin as well as norepinephrine, prescribers are cautious about combining it with other serotonergic medications (Haddad et al., 2022) [4].
- Guanfacine ER commonly causes drowsiness, especially early in treatment. Some people find this helpful if they also struggle with sleep, while others find it interferes with daytime alertness. Blood pressure monitoring is standard.
- Clonidine ER has a similar drowsiness and blood pressure profile to guanfacine but can be more sedating. It should not be stopped abruptly because sudden discontinuation can cause a rebound increase in blood pressure.
All four medications require discussion with a prescriber about your full medical history, including heart health, liver function, and any other medications you take. Side effects are one of the main reasons treatment is individualized: what causes problems for one person may be well tolerated by another.
How do non-stimulants compare to stimulants overall?
Stimulants remain the most-studied first-line pharmacological treatment for ADHD in adults, with a larger evidence base for symptom reduction. Non-stimulants generally show more modest symptom improvement in clinical trials, but they offer meaningful advantages in tolerability, misuse risk, and around-the-clock coverage (Khan et al., 2026) [5].
A 2026 systematic review and meta-analysis of randomized controlled trials found that stimulant medications consistently reduced core ADHD symptoms, while non-stimulants like viloxazine and guanfacine showed significant but clinically modest improvements on standardized ADHD rating scales (Khan et al., 2026) [5]. The review also noted that combined approaches (medication plus behavioral strategies) tended to produce the best functional outcomes.
The practical comparison often comes down to individual factors:
| Factor | Stimulants | Non-stimulants |
|---|---|---|
| Speed of effect | Hours | Weeks |
| Duration of action | Varies by formulation (4 to 16 hours) | Typically 24-hour coverage |
| Misuse potential | Present (Schedule II controlled substance) | None |
| Effect size on core symptoms | Larger in most trials | Moderate |
| Sleep impact | Can cause insomnia in some people | Alpha-2 agonists may improve sleep |
| Anxiety impact | Can worsen anxiety in some people | Alpha-2 agonists may reduce anxiety symptoms |
Neither class is universally better. The best medication is the one that adequately reduces your symptoms with side effects you can live with, and that determination requires working with a prescriber who knows your full clinical picture.
What new non-stimulant treatments are in development?
Research into new non-stimulant options is active, with several compounds in various stages of clinical trials. These include novel norepinephrine-targeting agents, glutamate modulators, and combination formulations designed to improve tolerability or extend coverage.
Centanafadine, a triple reuptake inhibitor affecting norepinephrine, dopamine, and serotonin, has been studied in adult ADHD trials. Mazindol, originally developed as an appetite suppressant, is being investigated for its effects on wakefulness and attention in ADHD. Research is also exploring whether certain existing medications used off-label (such as bupropion, which has noradrenergic and dopaminergic properties) might warrant formal ADHD indications based on accumulating evidence (Brancati et al., 2024) [3].
It is worth noting that pipeline medications are still experimental. Promising trial results do not guarantee approval, and it typically takes years for a new medication to move from clinical trials to a prescriber's toolkit. Still, the growing number of compounds in development reflects a recognition that the current options, while helpful, do not work for everyone, and that more personalized treatment strategies are needed (Newcorn et al., 2022) [2].
If you are wondering whether ADHD might be part of your picture, you can try our online ADHD self-test to help organize your thoughts before booking an appointment.
Infographic: key points about non stimulant adhd medications.
Each non-stimulant class works through a different mechanism, so switching between them can be worthwhile if the first option falls short.
Frequently asked questions
Are non-stimulant ADHD medications less effective than stimulants?
Non-stimulants generally show more modest symptom reduction in clinical trials compared to stimulants. But "less effective on average" does not mean less effective for you. Some adults respond better to a non-stimulant than to any stimulant they have tried, which is why individualized treatment matters (Khan et al., 2026).
Can you take a non-stimulant and a stimulant together?
Yes. Combining a stimulant with a non-stimulant (augmentation) is a recognized strategy when a stimulant alone does not fully address symptoms. A prescriber monitors the combination for interactions and adjusts doses as needed (Newcorn et al., 2022). This is not uncommon in clinical practice.
How long do non-stimulant medications take to start working?
Most non-stimulants take two to six weeks to reach full therapeutic effect. Atomoxetine is often the slowest (four to six weeks), while guanfacine and clonidine may show initial effects within two to three weeks. Patience during this period is important, and tracking symptoms daily can help you and your prescriber evaluate progress.
Do non-stimulant ADHD medications cause weight loss?
Atomoxetine and viloxazine can decrease appetite in some people, which may lead to modest weight changes. However, the appetite suppression is generally less pronounced than with stimulant medications. Alpha-2 agonists (guanfacine and clonidine) are not typically associated with appetite changes.
Can non-stimulants help with ADHD-related anxiety?
Guanfacine and clonidine, the alpha-2 agonists, may help reduce anxiety-related arousal because of their calming mechanism. Atomoxetine and viloxazine can sometimes worsen anxiety in some individuals, particularly early in treatment. Discuss your anxiety symptoms with your prescriber so they can factor this into the medication choice.
Are non-stimulant medications safe during pregnancy?
Safety data for ADHD medications during pregnancy is limited for all classes, including non-stimulants. This is a decision that requires careful discussion with both a prescriber and an obstetrician, weighing the risks of untreated ADHD against the potential risks of medication exposure. No ADHD medication currently has robust safety data for pregnancy.
Do you need to take non-stimulants every day?
Yes. Unlike some stimulant formulations that can be taken as needed, non-stimulants must be taken daily to maintain their therapeutic effect. Skipping doses can reduce effectiveness, and stopping alpha-2 agonists abruptly can cause rebound blood pressure increases. Always follow your prescriber's instructions for any changes.
Will a non-stimulant show up on a drug test?
Non-stimulant ADHD medications do not show up on standard drug screenings. This is one reason they may be preferred for adults in occupations that require regular drug testing or for individuals in substance use recovery programs.
Can adults get viloxazine prescribed for ADHD?
Viloxazine ER currently holds FDA approval only for pediatric ADHD (ages 6 to 17). Some clinicians prescribe it off-label for adults, particularly when other options have not been effective. Adult-specific trials are ongoing, and formal adult approval may follow if results are positive (Haddad et al., 2022).
How do I know if I should switch from a stimulant to a non-stimulant?
Common reasons to discuss a switch include persistent side effects (insomnia, significant anxiety, appetite loss) that do not improve with dose adjustments, a history of substance use, cardiovascular concerns, or simply not getting enough symptom relief. Your prescriber can help weigh whether switching, augmenting, or adjusting the current medication makes the most sense. For background on how the two classes compare, see our stimulants vs. non-stimulants overview.
Are non-stimulant medications covered by insurance?
Coverage varies by plan, country, and specific medication. In the US, most private insurance plans and Medicaid cover at least some non-stimulant options, though prior authorization may be required. In the UK, the NHS covers prescriptions for approved ADHD medications. In Canada and Australia, coverage depends on provincial or state formularies. Check with your insurer or prescriber's office before starting treatment.
What happens if a non-stimulant does not work?
If one non-stimulant does not provide adequate relief, a prescriber may try a different non-stimulant from the other class (switching from a norepinephrine reuptake inhibitor to an alpha-2 agonist, or vice versa), adjust the dose, add a stimulant, or explore off-label options. Treatment for ADHD is often a process of systematic trial and adjustment rather than a single decision. For more on the full range of medication options, visit our ADHD medications guide.
